High-dose therapy and autologous hematopoietic stem cell transplant in T-cell lymphoma: a single center experience. Issue 8 (August 2014)

• Record Type: Journal Article
• Authors: Cairoli, Anne; Ketterer, Nicolas; Barelli, Stefano; Duchosal, Michel A.
• Is Part Of: Leukemia & lymphoma. Volume 55:Issue 8(2014:Aug.)
• Page Start: 1827
• Page End: 1831
• Publication Date: 2014-08
• Subjects: Leukemia -- Periodicals; Lymphomas -- Periodicals; 616.99419
• DOI: 10.3109/10428194.2013.852666
• Languages: English
• ISSNs: 1042-8194

Abstract

<abstract> <title>Abstract</title> <p>We report here the long-term outcome of autologous stem cell transplant in peripheral T-cell lymphoma (PTCL). Forty-three consecutive patients with PTCL diagnosed between 2000 and 2011 were treated with high-dose chemotherapy (HDCT) and autologous stem cell transplant (ASCT) in our center. Diagnoses included PTCL-not otherwise specified (<italic>n</italic> = 19), anaplastic large cell lymphoma (<italic>n</italic> = 11), angioimmunoblastic T-cell lymphoma (<italic>n</italic> = 5), enteropathy-associated T-cell lymphoma (<italic>n</italic> = 5) and other rare subtypes (<italic>n</italic> = 3). Thirty-six patients with a median age of 50 years (range 22–65) were transplanted in first response and seven after relapse. After a median follow-up of 63 months, estimated overall survival at 12 years was 40%, progression-free survival at 12 years was 34% and event-free survival at 12 years was 30%. On univariate analysis, age less than 50 years and no B symptoms at diagnosis were significantly associated with prolonged overall and progression-free-survival. HDCT/ASCT for peripheral T-cell lymphoma can lead to long-term survival for patients responding to induction chemotherapy.</p> </abstract>